• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Bruce Cree Discusses Multiple Sclerosis Therapy in a Case Management Setting

Article

In this segment, Dr. Bruce Cree, Assistant Professor of Clinical Neurology, Department of Neurology, University of California San Francisco, discusses how he determines the most appropriate medications for his patients, and working with third-party payers.

Deciding which treatment is selected is based upon tolerability and patent preference. It is important to give patient's different treatment options available in managed care plans. Dr. Cree addresses the potential harm of using third-party preferred medications.

Related Videos
Eleanor Perfetto, PhD
Paula Rodríguez-Otero, MD, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Jonathan Strober, MD
Steven Manobianco, MD
Xiaotong Li, PhD, MS, Memorial Sloan Kettering Cancer Center
Related Content
neurons | Image credit: Matthieu - stock.adobe.com

Convolutional Neural Network Improves MS Lesion Segmentation

December 15th 2025
Article

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

Read More

AJMC Managed Care Cast

AJMC® Editors Reflect on Milestone Year and Look to 2026

December 16th 2025
Podcast

The editors in chief of AJMC discuss the key managed care research and news from 2025 as the journal celebrated its 30th anniversary.

Listen

Portland Oregon | Image Credit: © Andy - stock.adobe.com

Expanding Precision Care for Alzheimer Disease, Multiple Sclerosis

December 8th 2025
Article

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Read More

Managed Care Cast square image

Bright Lights, Dark Months: Understanding Seasonal Affective Disorder

December 9th 2025
Podcast

Discover more about seasonal affective disorder in this interview with Craig Sawchuk, PhD, LP, clinical psychologist at Mayo Clinic.

Listen

How expiring ACA subsidies could reshape coverage choices for employees and employers. | Image credit: @iQoncept-stock.adobe.com.jpeg

What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light

December 2nd 2025
Article

With ACA subsidies ending in 2025, Ben Light explains how rising premiums may push individuals toward ICHRAs and reshape employer health coverage strategy.

Read More

The data showed that patients taking rituximab had higher rates of all-cause hospitalization compared to those taking ocrelizumab. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Ocrelizumab Leads to Lower Hospitalization Rates vs Rituximab in MS

November 26th 2025
Article

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.